drugset / Trial / NCT02735850
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)
Phase 2
Withdrawn
Maastricht Radiation Oncology
Catholic University of the Sacred Heart · collabCopenhagen University Hospital at Herlev · collabKU Leuven · collabKarolinska Institutet · collabMaastricht University Medical Center · collabThe Netherlands Cancer Institute · collabUniversity of Oxford · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This will be a phase II trial testing if the combination of SBRT and L19-IL2 improves the progression free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). Treatment will be divided in two cohorts: patients eligible for ablative stereotactic body radiotherapy to all metastatic sites (treatment with curative intent) and patients not eligible for stereotactic body radiotherapy to all sites (life prolongation).
Timeline
- Start
- 2015-12
- Primary completion
- 2021-02
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darleukin | Protein / enzyme biologic | — | — |